1. Home
  2. Companies
  3. MYX
  4. Material Events

Mayne Pharma (ASX:MYX) — Material Events

ASX:MYX · 28 articles in the last 12 months · 100% assessed

Click a band to jump to that tier

Major 2 articles Significant 15 articles Notable 11 articles Not Assessed 0 articles
Major ≥90 Significant 75–89 Notable 50–74 Routine <50 Not assessed
Significant Score 75–89
15
FIRB Blocks Cosette’s Bid for Mayne Pharma, Scheme Faces CollapseHigh
FIRB objects to Cosette's acquisition of Mayne Pharma; scheme unlikely to proceed
21 Nov 2025 ·Scheme Update ·Unexpected ·85
Mayne Pharma’s NEXTSTELLIS® Gains PBS Listing, Slashing Costs for Australian WomenMedium
Mayne Pharma's NEXTSTELLIS® oral contraceptive listed on Australian PBS from October 2025
29 Sept 2025 ·ASX Announcement ·85
Mayne Pharma Doubles Underlying EBITDA on 5% Revenue Growth, Launches New Dermatology ProductsMedium
Mayne Pharma FY25 revenue up 5%, underlying EBITDA doubles; launches new dermatology products
29 Aug 2025 ·Results Presentation ·85
Mayne Pharma Launches Legal Battle Over Failed Cosette AcquisitionHigh
Mayne Pharma sues Cosette and partners for damages over terminated acquisition deal
18 Feb 2026 ·Litigation Announcement ·Unexpected ·85
Mayne Pharma Doubles EBITDA on 5% Revenue Growth, Eyes US Dermatology ExpansionMedium
Mayne Pharma FY25: 5% Revenue Growth, 105% EBITDA Increase, Strategic Acquisitions, Positive Cash Flow
29 Aug 2025 ·Financial Results ·85
Mayne Pharma’s FY25 – Revenue Growth Masks $93.8m Loss Amid Acquisition DisputeHigh
Mayne Pharma posts FY25 revenue growth but reports $93.8m net loss; acquisition scheme with Cosette delayed amid legal dispute
29 Aug 2025 ·Annual Financial Statements ·85
Takeovers Panel Orders Cosette to Restrict Closure of Mayne Pharma’s Salisbury Site Amid Scheme DisputeHigh
Takeovers Panel Orders Cosette to Restrict Closure of Mayne Pharma's Salisbury Site Amid Scheme Dispute
19 Nov 2025 ·Declaration of Unacceptable Circumstances and Orders ·Unexpected ·85
Mayne Pharma’s DistributeRx Launch Drives Prescription Growth and Cash SurgeMedium
Mayne Pharma posts 1% revenue growth and strong cash flow with DistributeRx launch exceeding forecasts
29 Apr 2026 ·Quarterly Financial Results ·85
Mayne Pharma Doubles EBITDA in FY25, Launches New Dermatology ProductsMedium
Mayne Pharma reports strong FY25 earnings growth, launches new dermatology products, and outlines FY26 growth strategy
29 Jan 2026 ·Annual General Meeting Presentation ·80
Mayne Pharma Faces Uncertain Appeal in Cosette Acquisition BattleMedium
Mayne Pharma faces appeal in acquisition dispute with Cosette Pharmaceuticals
10 Nov 2025 ·Legal Proceedings Update ·80
Treasurer Flags National Interest Risks Over Mayne Pharma DealHigh
Treasurer raises national interest concerns over Cosette's acquisition of Mayne Pharma citing potential closure of Adelaide site
31 Oct 2025 ·Scheme Update ·Unexpected ·80
Mayne Pharma Faces Key FIRB Deadline Amid Financing Uncertainty for Cosette DealMedium
Mayne Pharma updates on FIRB approval extension and financing risks for Cosette acquisition
18 Nov 2025 ·Scheme Update ·75
Mayne Pharma’s Women’s Health Growth Offsets Dermatology Price PressuresMedium
Mayne Pharma posts mixed FY26 start with strong Women’s Health growth, Dermatology margin gains, and strategic review underway
22 Dec 2025 ·Market Update ·75
Mayne Pharma Rebukes Cosette’s Attempted Scheme Termination Over FIRB HurdleHigh
Mayne Pharma rejects Cosette's purported termination of Scheme Implementation Deed over FIRB condition dispute
10 Dec 2025 ·ASX Announcement ·Unexpected ·75
Mayne Pharma Rebukes Cosette’s Latest Termination Threat Over FDA DisclosureHigh
Mayne Pharma rejects Cosette's new termination notice alleging SID breach over FDA disclosure
5 Aug 2025 ·ASX Announcement ·Unexpected ·75
Notable Score 50–74
11
Mayne Pharma Secures $14.4M Legal Costs from Cosette After Court RulingMedium
Mayne Pharma receives $14.4 million legal costs payment from Cosette Pharmaceuticals following court ruling
5 June 2026 ·Legal Proceedings Update ·70
Mayne Pharma Elevates CFO Aaron Gray to CEO in Smooth Leadership ShiftMedium
Mayne Pharma CEO steps down; CFO Aaron Gray appointed new CEO in planned leadership transition
23 Feb 2026 ·Management Change ·70
Mayne Pharma Awaits FIRB Nod Ahead of Crucial Court HearingMedium
Mayne Pharma updates on FIRB approval and court hearing for acquisition scheme
4 Nov 2025 ·Scheme Update ·70
Mayne Pharma’s Acquisition Scheme Hearing Set for November 3 Amid FIRB WaitMedium
Mayne Pharma Court Hearing Rescheduled to November 3 for Acquisition Scheme Approval
21 Oct 2025 ·Scheme of Arrangement Update ·70
FIRB Extends Deadline, Mayne Pharma Acquisition Court Date Pushed BackMedium
FIRB extends deadline for Mayne Pharma acquisition approval; court hearing rescheduled
7 Nov 2025 ·Regulatory Update ·70
Mayne Pharma FIRB Deadline Extended, Court Hearing Pushed to Nov 23Medium
Mayne Pharma FIRB Approval Deadline Extended; Court Hearing Rescheduled to 23 Nov 2025
20 Nov 2025 ·Scheme Update ·70
Takeovers Panel Extends Mayne Pharma-Cosette Deal Deadline Amid DisputeMedium
Takeovers Panel Issues Interim Orders Extending Mayne Pharma-Cosette Scheme Deadline
14 Nov 2025 ·Regulatory Announcement ·70
Mayne Pharma Denies Closure Rumors Amid FIRB Approval UncertaintyMedium
Mayne Pharma refutes closure rumors and seeks clarity on FIRB approval amid Scheme transaction dispute
8 Sept 2025 ·ASX Announcement ·Unexpected ·70
Mayne Pharma Secures $13.27M Legal Costs Win Over CosetteMedium
Mayne Pharma awarded $13.27M legal costs from Cosette Pharmaceuticals
22 May 2026 ·Legal Proceedings Outcome ·70
Mayne Pharma Acquisition Hits Regulatory Delay, Court Hearing in QuestionMedium
Mayne Pharma FIRB Approval Delayed, Court Hearing May Be Rescheduled
16 Oct 2025 ·Regulatory Update ·60
FIRB Extends Mayne Pharma Acquisition Deadline to November 17Medium
FIRB extends deadline for Mayne Pharma acquisition approval to 17 November 2025
13 Nov 2025 ·Regulatory Update ·60
Not Assessed Low Score, or missing data
0

No articles in this tier for the last 12 months.